他貝蘆單抗，Tabalumab，CAS:1143503-67-6， AntibodySystem Laboratories

貨號：DHJ85302

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75171.html

別名：LY2127399, CAS: 1143503-67-6

簡介：

Tabalumab (LY2127399) 是一種人源化的抗 BAFF (B細胞激活因子) 單克隆抗體 (IgG4 型)，對膜結合和可溶性 BAFF 具有中和活性。Tabalumab 可用于自身免疫性疾病，如類風濕性關節(jié)炎、腎衰竭和系統(tǒng)性紅斑狼瘡的研究。

貨號：DHJ85302

產(chǎn)品品牌：Antibodysystem

通用名：Tabalumab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：LY2127399

靶點;物種：Human CD257/BAFF/TNFSF13B

種類：Homo sapiens

受體鑒定：IgG4-kappa

CAS：1143503-67-6

存儲條件：

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

參考文獻：

Emerging B-Cell Therapies in Systemic Lupus Erythematosus. PMID: 33488082

The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. PMID: 23684423

Distinct binding mode of BAFF antagonist antibodies belimumab and tabalumab, analyzed by computer simulation. PMID: 36063219

Further thoughts about the ILLUMINATE studies of tabalumab in SLE. PMID: 26530320

Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. PMID: 23268367

Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? PMID: 28765121

Dose-escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma. PMID: 27350068

Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial. PMID: 23359344

Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. PMID: 28005265

The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials. PMID: 27220348

Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus. PMID: 26648084

Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey (Macaca fasicularis): A summary of three pre-clinical immunotoxicology evaluations. PMID: 25585959

Developmental Toxicity and Fertility Assessment in Rabbits with Tabalumab: A Human IgG4 Monoclonal Antibody. PMID: 26195315

Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. PMID: 27287072

Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples. PMID: 23625979

Efficacy and Safety of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population: Results From a Randomized, Placebo-Controlled, Phase 3 Trial (FLEX-O). PMID: 26203826

Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study. PMID: 27471815

Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor. PMID: 25258549

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. PMID: 26338095

Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. PMID: 25873635

Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study. PMID: 26535134

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. PMID: 26293163

An Enhanced Pre- and Postnatal Development Study in Cynomolgus Monkeys with Tabalumab: A Human IgG4 Monoclonal Antibody. PMID: 26195230

A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. PMID: 23599435

A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis. PMID: 25168268

Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation. PMID: 26780484

Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab. PMID: 27723281

Emerging antibodies for the treatment of multiple myeloma. PMID: 27195659

eLetter: Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors by M Genovese. PMID: 23396663

Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE). PMID: 28164726

Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis. PMID: 31617269

B-cell survival factors in autoimmune rheumatic disorders. PMID: 26288664

Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? PMID: 22547203

B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? PMID: 25723853

Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis. PMID: 31910414

The efficacy of novel B cell biologics as the future of SLE treatment: a review. PMID: 25149393

B-cell targeted therapeutics in clinical development. PMID: 23566679

Which are the antibodies to watch in 2013? PMID: 23254906

Update on clinical trials in systemic lupus erythematosus. PMID: 27314466

Targeting BAFF/BLyS in lupus: is the glass half-full or half-empty? PMID: 26590173

Antibodies to watch in 2013: Mid-year update. PMID: 23727858

What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us? PMID: 35794296

Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. PMID: 24521424

B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases. PMID: 27655102

Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. PMID: 22171583

The safety and efficacy of biologic agents in treatment of systemic lupus erythematosus: A network meta-analysis. PMID: 31777515

[Advances of using antibody against B cell activating factor for treatment of autoimmune diseases]. PMID: 35355463

Treating multiple sclerosis with monoclonal antibodies: a 2013 update. PMID: 23448220

[State of the art treatment of progressive or refractory multiple myeloma]. PMID: 25268212

Current Understanding and Unknown Aspects of the Treatment of Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Opportunities for Future Studies. PMID: 32228425

External Validation of the Lupus Multivariable Outcome Score for Systemic Lupus Erythematosus Trials. PMID: 35962577

Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-analysis. PMID: 28673504

Biotherapies in systemic lupus erythematosus: New targets. PMID: 27663753

Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus. PMID: 29426575

Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. PMID: 31181988

BAFF inhibition does not significantly impair immunization responses in patients with rheumatoid arthritis. PMID: 26621128

Scoring personalized molecular portraits identify Systemic Lupus Erythematosus subtypes and predict individualized drug responses, symptomatology and disease progression. PMID: 35947992

A Bayesian gene network reveals insight into the JAK-STAT pathway in systemic lupus erythematosus. PMID: 31790472

[Therapeutic monoclonal antibodies against multiple myeloma]. PMID: 25626316

Unexpected Potency Differences between B-Cell-Activating Factor (BAFF) Antagonist Antibodies against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound. PMID: 27440419